Medpredict, Dec 2010, Pages: 122
strategies
- Cost of therapy and duration of treatment
- Side effects: rash vs. anemia
This report provides essential strategic insight for key stakeholders in the hepatitis C virus market at a significant
Datamonitor, Dec 2009, Pages: 160
vaccines in infectious diseases
Key findings
Overview
HepatitisB therapeutic vaccines
Rationale for development of therapeutic vaccines against hepatitisB
Disease background: over 360 million people
Datamonitor, June 2010, Pages: 108
A and B populations by age for the US, Japan, France, Germany, Italy, Spain and the UK (%)
Figure: Current hepatitis C and human immunodeficiency virus prevalence among hemophilia and general populations
Datamonitor, Dec 2010, Pages: 126
damage and cirrhosis
Hepatocellular cancer
Risk factors
Hepatitis infection
HepatitisBHepatitis C
Alcohol
Aflatoxin exposure
Genetic predisposition
Diagnosis and screening
Complexities of early
Datamonitor, Dec 2009, Pages: 187
team
Disclaimer
StakeholderInsight: Non-Hodgkin's Lymphomas Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)
Markets and Markets, Feb 2011, Pages: 264
market and its segments
- To identify major stakeholders in the market and draw a competitive landscape for market leaders for each of the drug delivery technology market.
- To analyze opportunities
Frost & Sullivan, June 2005
(1999-2006)
- - 5. Incidence of HepatitisB--World (1999-2006)
- - 6. Prevalence of HIV--World (1999-2006)
- - 7. Number of Diagnostic Testing Facilities--USA (1999-2007)
Advances in Point
Datamonitor, March 2008, Pages: 123
in the prophylaxis and treatment of infections. CHAPTER 1 EXECUTIVE SUMMARY 3
Scope of the analysis 3
Datamonitor insight into biologics infectious diseases 3
Contributing experts 6
Related reports 6
Upcoming related
